Cargando…

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)

BACKGROUND: NAFLD impacts patient reported outcomes (PROs). Our aim was to assess the impact of NAFLD on patients’ HRQOL. METHODS: National Health and Nutrition Examination Survey (NHANES) 2001–2011 data were used to identify adult patients with NAFLD [Fatty Liver Index (FLI) > 60 in absence of o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golabi, Pegah, Otgonsuren, Munkhzul, Cable, Rebecca, Felix, Sean, Koenig, Aaron, Sayiner, Mehmet, Younossi, Zobair M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746896/ https://www.ncbi.nlm.nih.gov/pubmed/26860700 http://dx.doi.org/10.1186/s12955-016-0420-z

Ejemplares similares

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
por: Golabi, Pegah, et al.
Publicado: (2017)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States
por: Golabi, Pegah, et al.
Publicado: (2016)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
por: Golabi, Pegah, et al.
Publicado: (2019)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States
por: Shahab, Omer, et al.
Publicado: (2019)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
por: Golabi, Pegah, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States
por: Paik, James M., et al.
Publicado: (2020)

Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
por: Shahab, Omer, et al.
Publicado: (2018)

Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
por: Golabi, Pegah, et al.
Publicado: (2020)

Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States
por: Golabi, Pegah, et al.
Publicado: (2019)

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
por: Younossi, Zobair M., et al.
Publicado: (2021)

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
por: Arshad, Tamoore, et al.
Publicado: (2018)

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease
por: Mehta, Rohini, et al.
Publicado: (2016)

Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection
por: Younossi, Zobair M., et al.
Publicado: (2021)

Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease
por: Karrar, Azza, et al.
Publicado: (2019)

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
por: Paik, James M., et al.
Publicado: (2020)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality
por: Golabi, Pegah, et al.
Publicado: (2019)

Exercise as an intervention for patients with end-stage liver disease: Systematic review
por: Locklear, Cameron T., et al.
Publicado: (2018)

Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016
por: Paik, James M, et al.
Publicado: (2020)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Association of physical activity and fine motor performance in individuals with type 2 diabetes mellitus and/or non-alcoholic fatty liver disease
por: Weinstein, Ali A., et al.
Publicado: (2023)

The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
por: Paik, James M., et al.
Publicado: (2023)

Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Younossi, Zobair M., et al.
Publicado: (2021)

Interrelationship between physical activity and depression in nonalcoholic fatty liver disease
por: Weinstein, Ali A, et al.
Publicado: (2022)

The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007‐2017
por: Paik, James M., et al.
Publicado: (2021)

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2018)

Major Histocompatibility Complex Class I‐Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease
por: Karrar, Azza, et al.
Publicado: (2020)

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
por: Alqahtani, Saleh A., et al.
Publicado: (2021)

Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
por: Baranova, Ancha, et al.
Publicado: (2013)

Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data
por: Paik, James M., et al.
Publicado: (2021)

Sarcopenia, healthy living, and mortality in patients with chronic liver diseases
por: Van Dongen, Catherine, et al.
Publicado: (2022)

Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices
por: Younossi, Zobair M., et al.
Publicado: (2021)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v3rg817rqoj0v613tganpelc05